Major Adverse Cardiovascular Events (MACE) | Norton Healthcare

Indication: Major Adverse Cardiovascular Events (MACE)

SELECT – Semaglutide effects on cardiovascular outcomes in people with overweight or obesity

Subjects w/CV disease & overweight/obese

Drug Study

Principal Investigator: Joseph Lash, M.D.
Norton Heart & Vascular Institute

Sponsor: Novo Nordisk, Inc.

Learn more at

Email for more information:

Search our entire site.

Schedule an Appointment

Select an appointment date and time from available spots listed below.